These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 18353594

  • 1. Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States.
    Biedenbach DJ, Jones RN, Fritsche TR.
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):240-4. PubMed ID: 18353594
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q, Xu Y, Chen M, Wang H, Sun H, Hu Y, Zhang R, Duan Q, Zhuo C, Cao B, Liu Y, Yu Y, Sun Z, Chu Y.
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [Abstract] [Full Text] [Related]

  • 3. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
    Seral C, Suárez L, Rubio-Calvo C, Gómez-Lus R, Gimeno M, Coronel P, Durán E, Becerril R, Oca M, Castillo FJ.
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
    [Abstract] [Full Text] [Related]

  • 5. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA, Farrell DJ, Sader HS, Jones RN.
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [Abstract] [Full Text] [Related]

  • 6. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

  • 7. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
    Sader HS, Gales AC, Granacher TD, Pfaller MA, Jones RN, SENTRY Study Group (Latin America).
    Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
    [Abstract] [Full Text] [Related]

  • 8. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M, Browne FA, Jacobs MR, Appelbaum PC.
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [Abstract] [Full Text] [Related]

  • 9. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
    Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, Alexander Project Group.
    J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries.
    Lee MY, Ko KS, Oh WS, Park S, Lee JY, Baek JY, Suh JY, Peck KR, Lee NY, Song JH.
    Int J Antimicrob Agents; 2006 Jul; 28(1):14-8. PubMed ID: 16777383
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA.
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [Abstract] [Full Text] [Related]

  • 12. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L.
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective.
    Sahm DF, Brown NP, Thornsberry C, Jones ME.
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):16-24. PubMed ID: 18931467
    [Abstract] [Full Text] [Related]

  • 14. In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
    Jones RN, Biedenbach DJ, Croco MA, Barrett MS.
    Diagn Microbiol Infect Dis; 1998 Aug; 31(4):573-8. PubMed ID: 9764398
    [Abstract] [Full Text] [Related]

  • 15. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy.
    Stefani S, Mezzatesta ML, Fadda G, Mattina R, Palù G, Rossano F, Tufano MA, Schito GC, Nicoletti G.
    J Chemother; 2008 Oct; 20(5):561-9. PubMed ID: 19028617
    [Abstract] [Full Text] [Related]

  • 16. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
    Pottumarthy S, Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
    [Abstract] [Full Text] [Related]

  • 17. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.
    Sahm DF, Brown NP, Draghi DC, Evangelista AT, Yee YC, Thornsberry C.
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):8-15. PubMed ID: 18931466
    [Abstract] [Full Text] [Related]

  • 18. PROTEKT 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan.
    Inoue M, Kohno S, Kaku M, Yamaguchi K, Igari J, Yamanaka K.
    Int J Infect Dis; 2005 Jan; 9(1):27-36. PubMed ID: 15603993
    [Abstract] [Full Text] [Related]

  • 19. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000].
    Melo-Cristino J, Fernandes ML, Serrano N, Grupo de Estudo Português de Bactérias Patogénicas Respiratórias.
    Acta Med Port; 2001 Jan; 14(5-6):459-68. PubMed ID: 11878155
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.
    Farrell DJ, Sader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, Jones RN.
    Int J Antimicrob Agents; 2010 Jun; 35(6):537-43. PubMed ID: 20211548
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.